Spinal Muscular Atrophy (SMA) Clinical Trial
Official title:
Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development
Spinal muscular atrophy (SMA) is the leading genetic cause of death of infants. Strong preclinical evidence suggests that effective therapy must be delivered as early as possible to prevent progression of the disease. The primary study objective will be to identify prognostic and surrogate biomarkers of disease progression that will facilitate the execution of therapeutic SMA clinical trials in infants.
Aim 1. To establish the validity of putative physiological SMA biomarkers in the immediate
postnatal period. A longitudinal, natural history examination of physiological markers of
muscle innervation will be performed in healthy and SMA infants. The first week of life is
the ideal first time point, with visits occurring at scheduled visits up to the age two.
Compound motor action potential (CMAP) amplitude and electrical impedance myography (EIM)
will be examined and will be correlated with motor function. Each of these is associated with
muscle innervation and provides information on the number and function of lower motor neurons
in the spinal cord, the cellular target of SMA therapeutic interventions. This trial will
establish the natural history of these putative SMA biomarkers as the disease evolves in
affected infants. Moreover, our approach will allow for measurements in pre-symptomatic and
early symptomatic subjects and determine their predictive value.
Aim 2. To establish the validity of putative molecular SMA biomarkers in the immediate
postnatal period. Survival Motor Neuron (SMN2) copy number is a valid, predictive molecular
SMA biomarker; however, it is fixed, and therefore not useful as a biomarker of clinical
progression or response to therapy. SMN messenger Ribonucleic acid (mRNA) ( and protein
expression is variable in different cell types and, in mice, naturally decreases with age
postnatally. In this study, SMN expression levels will be measured longitudinally in SMA
patients and controls. Additional putative molecular SMA markers that have been identified to
correlate with motor function will be determined in an effort to distinguish between
predictive markers that change prior to development of weakness and those that change as a
consequence of weakness.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04174157 -
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
|
||
| Recruiting |
NCT05354414 -
Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy
|
N/A | |
| Recruiting |
NCT05115110 -
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
|
Phase 2/Phase 3 | |
| Terminated |
NCT02876094 -
Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
| Recruiting |
NCT05747261 -
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05335876 -
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
|
Phase 3 | |
| Withdrawn |
NCT01663584 -
Multi-disease Carrier Screening Test Validation
|
N/A |